Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Atea Pharmaceuticals stock price, quote, forecast and news

AVIR
US04683R1068

Price

3.44
Today +/-
+0
Today %
+0 %
P

Atea Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Atea Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Atea Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Atea Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Atea Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Atea Pharmaceuticals Stock Price History

DateAtea Pharmaceuticals Price
9/27/20243.44 undefined
9/26/20243.44 undefined
9/25/20243.43 undefined
9/24/20243.50 undefined
9/23/20243.45 undefined
9/20/20243.67 undefined
9/19/20243.82 undefined
9/18/20243.99 undefined
9/17/20244.02 undefined
9/16/20243.89 undefined
9/13/20243.87 undefined
9/12/20243.67 undefined
9/11/20243.67 undefined
9/10/20243.71 undefined
9/9/20243.67 undefined
9/6/20243.60 undefined
9/5/20243.62 undefined
9/4/20243.63 undefined
9/3/20243.63 undefined

Atea Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Atea Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Atea Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Atea Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Atea Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Atea Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Atea Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Atea Pharmaceuticals’s growth potential.

Atea Pharmaceuticals Revenue, EBIT and net profit per share

DateAtea Pharmaceuticals RevenueAtea Pharmaceuticals EBITAtea Pharmaceuticals Net Income
2027e272.14 M undefined0 undefined47.36 M undefined
2026e321.34 M undefined-283.56 M undefined-59.41 M undefined
2025e7.73 M undefined-287.2 M undefined-221.73 M undefined
2024e0 undefined-256.4 M undefined-219.15 M undefined
20230 undefined-120.01 M undefined-135.96 M undefined
20220 undefined-111.2 M undefined-115.9 M undefined
2021351.4 M undefined231.9 M undefined121.2 M undefined
202048.6 M undefined12 M undefined-10.9 M undefined
20190 undefined-14.6 M undefined-14 M undefined
20180 undefined-9.5 M undefined-9.1 M undefined

Atea Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2018201920202021202220232024e2025e2026e2027e
00483510007321272
---631.25----4,485.71-15.26
----------
0000000000
-9-1412231-111-120-256-287-2830
--25.0065.81----4,100.00-88.16-
-9-14-10121-115-135-219-221-5947
-55.56-28.57-1,310.00-195.0417.3962.220.91-73.30-179.66
80.780.782.488.283.283.390000
----------
Details

Keystats

ⓘ

Revenue and Growth

The Atea Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Atea Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201820192020202120222023
           
34.521.7850.1764.4646.7578.11
005.8000
000000
000000
0.20.27.5814.212.35
34.721.9863.4772.4660.9590.46
0.1000.24.13.12
000000
000000
000000
000000
0.10.10.10.31.71.4
0.20.10.10.55.84.51
34.922863.5772.9666.7594.97
           
69.169.10.10.10.10.08
44.6612.9654701.1750.74
-40.2-54.2-65.256-59.9-195.84
0000-700207
000000
32.919.5547.8710.1640.6555.19
0.40.50.14.52.64.25
1.41.914.449.815.828.12
00301.42.60.10
000000
000000
1.82.4315.956.918.532.38
000000
000000
0.10.105.97.77.4
0.10.105.97.77.4
1.92.5315.962.826.239.78
34.822863.7772.9666.8594.97
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Atea Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Atea Pharmaceuticals's financial health and stability.

Assets

Atea Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Atea Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Atea Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Atea Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201820192020202120222023
-9-14-10121-115-135
000000
000000
00300-247-4616
0114798883
000000
000000
-7-12296-87-121-85
0000-10
0000-45540
0000-45340
000000
000000
270531100
270531100
------
000000
19-12828-85-576-44
-7.9-12.8296.7-87-122.9-85.4
000000

Atea Pharmaceuticals stock margins

The Atea Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Atea Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Atea Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Atea Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Atea Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Atea Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Atea Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Atea Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Atea Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Atea Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Atea Pharmaceuticals Margin History

Atea Pharmaceuticals Gross marginAtea Pharmaceuticals Profit marginAtea Pharmaceuticals EBIT marginAtea Pharmaceuticals Profit margin
2027e0 %0 %17.4 %
2026e0 %-88.24 %-18.49 %
2025e0 %-3,713.46 %-2,866.94 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %65.99 %34.49 %
20200 %24.69 %-22.43 %
20190 %0 %0 %
20180 %0 %0 %

Atea Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Atea Pharmaceuticals earnings per share therefore indicates how much revenue Atea Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Atea Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Atea Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Atea Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Atea Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Atea Pharmaceuticals Revenue, EBIT and net profit per share

DateAtea Pharmaceuticals Sales per ShareAtea Pharmaceuticals EBIT per shareAtea Pharmaceuticals Earnings per Share
2027e3.22 undefined0 undefined0.56 undefined
2026e3.81 undefined0 undefined-0.7 undefined
2025e0.09 undefined0 undefined-2.63 undefined
2024e0 undefined0 undefined-2.6 undefined
20230 undefined-1.44 undefined-1.63 undefined
20220 undefined-1.34 undefined-1.39 undefined
20213.98 undefined2.63 undefined1.37 undefined
20200.59 undefined0.15 undefined-0.13 undefined
20190 undefined-0.18 undefined-0.17 undefined
20180 undefined-0.12 undefined-0.11 undefined

Atea Pharmaceuticals business model

Atea Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for infectious diseases. The company is headquartered in Boston, Massachusetts, and was founded in 2012. Atea Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Atea Pharmaceuticals SWOT Analysis

Strengths

Atea Pharmaceuticals Inc is known for its robust research and development capabilities, which enable the company to develop innovative and effective pharmaceutical products. This strength allows them to stay at the forefront of the industry with cutting-edge solutions.

The company has an extensive drug pipeline, with multiple potential blockbuster drugs in development. This strong portfolio provides Atea Pharmaceuticals Inc with a competitive advantage and opportunities for future growth.

Weaknesses

Atea Pharmaceuticals Inc relies heavily on external funding sources to finance its research and development activities. This dependence on external investors or partnerships poses a potential risk if funding sources become limited or unavailable.

Despite its strengths, Atea Pharmaceuticals Inc has a relatively limited market presence compared to some of its larger competitors. Building a strong brand and expanding market reach may be a challenge for the company.

Opportunities

The increasing global demand for antiviral drugs presents a significant opportunity for Atea Pharmaceuticals Inc. Their expertise in this field positions them well to capture a larger market share and capitalize on the growing need for effective antiviral therapies.

Expanding into emerging markets, especially in regions with high incidences of viral infections, could provide Atea Pharmaceuticals Inc with new revenue streams and a larger customer base.

Threats

The pharmaceutical industry is highly competitive, with numerous well-established players and new entrants constantly emerging. Atea Pharmaceuticals Inc faces the constant threat of competition, which may impact its market share and profitability.

The pharmaceutical industry is heavily regulated, and Atea Pharmaceuticals Inc must adhere to various regulatory requirements and obtain necessary approvals for its products. Any delays or failures in obtaining approvals can significantly impact the company's operations and financial performance.

Atea Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Atea Pharmaceuticals historical P/E ratio, EBIT, and P/S ratio.

Atea Pharmaceuticals shares outstanding

The number of shares was Atea Pharmaceuticals in 2023 — This indicates how many shares 83.39 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Atea Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Atea Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Atea Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Atea Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Atea Pharmaceuticals.

Atea Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.78 -0.48  (38.49 %)2024 Q2
3/31/2024-0.62 -0.75  (-21.2 %)2024 Q1
12/31/2023-0.51 -0.47  (7.22 %)2023 Q4
9/30/2023-0.49 -0.4  (17.73 %)2023 Q3
6/30/2023-0.48 -0.34  (29.08 %)2023 Q2
3/31/2023-0.49 -0.43  (11.72 %)2023 Q1
12/31/2022-0.46 -0.41  (10.68 %)2022 Q4
9/30/2022-0.45 -0.1  (77.89 %)2022 Q3
6/30/2022-0.53 -0.38  (28.81 %)2022 Q2
3/31/2022-0.59 -0.51  (14.17 %)2022 Q1
1
2

Eulerpool ESG Scorecard© for the Atea Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

43/ 100

🌱 Environment

45

👫 Social

52

🏛️ Governance

31

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Atea Pharmaceuticals list of shareholders

%
Name
Stocks
Change
Date
8.28697 % EcoR1 Capital, LLC6,995,861012/31/2023
7.95824 % BlackRock Institutional Trust Company, N.A.6,718,342220,47712/31/2023
7.01848 % JPM Partner LLC5,925,000012/31/2023
6.47012 % BML Capital Management LLC5,462,079662,07912/31/2023
6.33814 % Fidelity Management & Research Company LLC5,350,659-1,101,89112/31/2023
5.44860 % The Vanguard Group, Inc.4,599,71026,27012/31/2023
4.82912 % Tang Capital Management, LLC4,076,74143,27812/31/2023
2.94437 % Bain Capital Life Sciences Investors, LLC2,485,638012/31/2023
2.41221 % BlackRock Financial Management, Inc.2,036,389786,61712/31/2023
2.14157 % Geode Capital Management, L.L.C.1,807,91282,18312/31/2023
1
2
3
4
5
...
10

Atea Pharmaceuticals Executives and Management Board

Dr. Jean-Pierre Sommadossi67
Atea Pharmaceuticals Chairman of the Board, President, Chief Executive Officer, Founder (since 2012)
Compensation 5.88 M
Dr. Janet Hammond63
Atea Pharmaceuticals Chief Development Officer
Compensation 2.11 M
Ms. Andrea Corcoran60
Atea Pharmaceuticals Chief Financial Officer, Executive Vice President - Legal , Secretary
Compensation 1.96 M
Dr. Maria Horga54
Atea Pharmaceuticals Chief Medical Officer
Compensation 1.85 M
Mr. John Vavricka59
Atea Pharmaceuticals Chief Commercial Officer
Compensation 1.52 M
1
2
3

Atea Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Roche Holding Stock
Roche Holding
SupplierCustomer-0,16-0,65-0,370,09-0,42-
1

Most common questions regarding Atea Pharmaceuticals

What values and corporate philosophy does Atea Pharmaceuticals represent?

Atea Pharmaceuticals Inc represents values of innovation, collaboration, and dedication to improving global health. With a strong corporate philosophy focused on advancing antiviral therapies, the company is committed to delivering transformative solutions for infectious diseases. Atea Pharmaceuticals prioritizes research and development, employing cutting-edge science and technology to develop novel therapeutics that target viral replication. By focusing on the fundamental biology of viruses, Atea Pharmaceuticals aims to provide effective antiviral therapies that address unmet medical needs. Through its commitment to excellence and patient-centric approach, Atea Pharmaceuticals strives to make a significant impact in the field of infectious diseases.

In which countries and regions is Atea Pharmaceuticals primarily present?

Atea Pharmaceuticals Inc is primarily present in the United States, with headquarters in Boston, Massachusetts. As a biopharmaceutical company focused on discovering and developing antiviral therapeutics, Atea Pharmaceuticals Inc has a strong presence in the healthcare sector in the US. With a dedication to advancing innovative treatments, Atea Pharmaceuticals Inc is actively involved in research and collaborations within the US healthcare industry.

What significant milestones has the company Atea Pharmaceuticals achieved?

Atea Pharmaceuticals Inc has achieved significant milestones in its journey. Some notable accomplishments include the successful completion of Phase 1 clinical trials for its antiviral candidate, AT-527. The company also obtained Fast Track designation from the U.S. FDA for AT-527 as a potential treatment for COVID-19. Atea Pharmaceuticals Inc formed strategic collaborations, such as the partnership with Roche to develop and distribute AT-527 globally. Additionally, the company went public on the Nasdaq stock exchange, raising funds to further progress its antiviral programs. These accomplishments reflect Atea Pharmaceuticals Inc's dedication to advancing innovative therapies and its potential for growth in the biopharmaceutical industry.

What is the history and background of the company Atea Pharmaceuticals?

Atea Pharmaceuticals Inc. is a leading biopharmaceutical company that focuses on discovering and developing novel antiviral therapies. With a rich history and background, Atea Pharmaceuticals was founded in 2014 and is headquartered in Boston, Massachusetts, USA. The company is dedicated to addressing the urgent global health challenges posed by viral diseases. Atea Pharmaceuticals has a strong pipeline of innovative antiviral therapeutics that specifically target RNA-based viruses, including the current focus on developing a potential oral direct-acting antiviral for the treatment of COVID-19. With its cutting-edge science and committed team, Atea Pharmaceuticals remains at the forefront of developing groundbreaking therapies to combat viral infections.

Who are the main competitors of Atea Pharmaceuticals in the market?

The main competitors of Atea Pharmaceuticals Inc in the market are other pharmaceutical companies involved in antiviral therapeutics development and production. Some prominent competitors in this space include Gilead Sciences Inc, Merck & Co Inc, Johnson & Johnson, GlaxoSmithKline Plc, and AbbVie Inc. These companies operate in similar therapeutic areas and may have overlapping product portfolios targeting viral infections, including COVID-19. Atea Pharmaceuticals Inc faces competition in the race for the development of effective antiviral treatments, with each competitor striving to create innovative solutions to combat viral diseases.

In which industries is Atea Pharmaceuticals primarily active?

Atea Pharmaceuticals Inc is primarily active in the biopharmaceutical industry.

What is the business model of Atea Pharmaceuticals?

Atea Pharmaceuticals Inc is a biopharmaceutical company with a focus on discovering, developing, and commercializing antiviral therapeutics. Their business model is centered around targeting the replication process of viral infections, including RNA viruses like SARS-CoV-2 (COVID-19). By developing innovative nucleotide analogs, Atea aims to address unmet medical needs and provide effective treatments for viral diseases. As a leading pharmaceutical company, Atea Pharmaceuticals Inc combines cutting-edge science, strategic partnerships, and a patient-centric approach to revolutionize antiviral therapies and improve global healthcare.

What is the P/E ratio of Atea Pharmaceuticals 2024?

The Atea Pharmaceuticals P/E ratio is -1.31.

What is the P/S ratio of Atea Pharmaceuticals 2024?

The Atea Pharmaceuticals P/S ratio is 0.

What is the AlleAktien quality score of Atea Pharmaceuticals?

The AlleAktien quality score for Atea Pharmaceuticals is 1/10.

What is the revenue of Atea Pharmaceuticals 2024?

The revenue cannot currently be calculated for Atea Pharmaceuticals.

How high is the profit of Atea Pharmaceuticals 2024?

The expected Atea Pharmaceuticals profit is -219.15 M USD.

What is the business model of Atea Pharmaceuticals

Atea Pharmaceuticals Inc is an innovative company specializing in the research and development of antiviral therapies to combat life-threatening virus infections. The company was founded in 2014 and is headquartered in Boston, Massachusetts. Atea Pharmaceuticals' business model is based on three main divisions: research and development, medical marketing and sales, and clinical research. In the research and development department, new antiviral medications are designed, researched, and tested to develop innovative therapies against viruses such as RNA viruses, influenza, SARS-CoV-2, and many more. Atea Pharmaceuticals has specialized particularly in RNA viruses, including Respiratory Syncytial Virus (RSV) and Hepatitis C Virus (HCV). The company has a special focus on viral diseases that can be particularly severe in certain patient populations, such as immunocompromised individuals, pregnant women, and older people. Products from Atea Pharmaceuticals include AT-527, a direct-acting antiviral therapy developed for the treatment of RNA viruses, including COVID-19. AT-527 is currently in Phase 2 clinical trials (as of August 2021). Another product in the portfolio is AT-752, a potential universal influenza virus blocker that is still in the preclinical development phase. Furthermore, Atea Pharmaceuticals focuses on collaborating with partner companies to develop and market antiviral therapies. For example, Atea has partnered with AbbVie to work together on the development of AT-527. To maximize the success of its products in practice, Atea Pharmaceuticals also employs an extensive marketing and sales plan. This includes efforts to publish key results and performance data from current and future clinical studies. As a result, positive results from a Phase 1 clinical study of AT-527 were published in December 2020, which found a significant reduction in viral load in COVID-19 patients. A Phase 2 clinical trial for AT-527 is currently underway. In conclusion, Atea Pharmaceuticals' business model focuses on the development of innovative antiviral therapies, particularly for RNA viruses, to combat life-threatening virus infections. With this goal in mind, research and development, clinical research, and medical marketing and sales are conducted comprehensively. The company has a partnership with AbbVie and offers products like AT-527, while continuing to work on the development of new products.

What is the Atea Pharmaceuticals dividend?

Atea Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Atea Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Atea Pharmaceuticals or the company does not pay out a dividend.

What is the Atea Pharmaceuticals ISIN?

The ISIN of Atea Pharmaceuticals is US04683R1068.

What is the Atea Pharmaceuticals ticker?

The ticker of Atea Pharmaceuticals is AVIR.

How much dividend does Atea Pharmaceuticals pay?

Over the past 12 months, Atea Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Atea Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Atea Pharmaceuticals?

The current dividend yield of Atea Pharmaceuticals is .

When does Atea Pharmaceuticals pay dividends?

Atea Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Atea Pharmaceuticals?

Atea Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Atea Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Atea Pharmaceuticals located?

Atea Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Atea Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Atea Pharmaceuticals from 9/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did Atea Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of Atea Pharmaceuticals in the year 2023?

In the year 2023, Atea Pharmaceuticals distributed 0 USD as dividends.

In which currency does Atea Pharmaceuticals pay out the dividend?

The dividends of Atea Pharmaceuticals are distributed in USD.

All fundamentals about Atea Pharmaceuticals

Our stock analysis for Atea Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Atea Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.